CMOPF (Cosmo NV) 3-Year RORE % : 23.01% (As of Dec. 2025)


CMOPF Cosmo NV CMOPF
79 GF Score
Price $83.69
GF Value $54.35
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Cosmo NV 3-Year RORE %?

Cosmo NV CMOPF 79 3-Year RORE % is 23.01 as of Dec. 2025. GuruFocus rates CMOPF with a GF Score™ of 79/100 and a GF Value™ of $54.35 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 937 Drug Manufacturers companies, Cosmo NV ranks better than 68.41% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Cosmo NV's 3-Year RORE % for the quarter that ended in Dec. 2025 was 23.01%.

The industry rank for Cosmo NV's 3-Year RORE % or its related term are showing as below:

CMOPF's 3-Year RORE % is ranked better than
68.41% of 937 companies
in the Drug Manufacturers industry
Industry Median: 3.09 vs CMOPF: 23.01

Cosmo NV  (OTCPK:CMOPF) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Cosmo NV 3-Year RORE % Related Terms


Cosmo NV 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Cosmo NV's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cosmo NV 3-Year RORE % Chart

Cosmo NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -297.74 199.66 622.90 157.59 23.01

Cosmo NV Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 622.90 31.16 157.59 109.23 23.01

CMOPF vs LLY, JNJ, ABBV: 3-Year RORE % Comparison

For the Drug Manufacturers - General subindustry, Cosmo NV's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosmo NV 3-Year RORE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Cosmo NV's 3-Year RORE % falls into.


CMOPF
79GF Score
Cosmo NV CMOPF
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cosmo NV 3-Year RORE % Calculation

Cosmo NV's 3-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.262--0.731 )/( 7.634-5.596 )
=0.469/2.038
=23.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 23.01 mean?
Cosmo NV (CMOPF) has a 3-Year RORE % of 23.01 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Cosmo NV and its competitors. According to the industry distribution chart, Cosmo NV ranks #296 out of 937 companies in the Drug Manufacturers industry, placing it in the top 31.6%.
Is Cosmo NV's 3-Year RORE % too high?
Cosmo NV's current 3-Year RORE % is 23.01. The Drug Manufacturers industry median 3-Year RORE % is 3.09. Cosmo NV's value of 23.01 is 644.7% above this industry median. Based on the distribution chart, Cosmo NV ranks #296 out of 937 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cosmo NV has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's 3-Year RORE % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #296 out of 937 companies for 3-Year RORE %. This puts Cosmo NV in the upper half of its industry. The industry median 3-Year RORE % is 3.09. Cosmo NV's value of 23.01 is 644.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.09, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo NV's current 3-Year RORE % of 23.01 is 644.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Cosmo NV and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current 3-Year RORE % is 23.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (CMOPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $54.35, compared to a current price of $83.69 — trading 54% above its estimated fair value. The current 3-Year RORE % is 23.01 and 644.7% above the Drug Manufacturers industry median of 3.09. Cosmo NV's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Cosmo NV (CMOPF), the current 3-Year RORE % is 23.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cosmo NV (CMOPF) Overvalued in 2026?

Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued. The current stock price of $83.69 is trading 54% above its estimated GF Value™ of $54.35. GuruFocus considers Cosmo NV to be Significantly Overvalued.

Key valuation signals for CMOPF:

  • 3-Year RORE %: 23.01
  • GF Value™: $54.35 vs. price of $83.69 (54% above fair value)
  • GF Score™: 79/100 with 3 warning signs
  • Industry Position: 644.7% above the Drug Manufacturers median (#296 of 937)

No single metric tells the full story. See the CMOPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cosmo NV Business Description

Address 91/94 North Wall Quay, 7th Floor, One North Dock, Dublin, IRL, D01 H7V7
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
79GF Score

Get the complete analysis for CMOPF

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$83.69
Price
$54.35
GF Value